Antengene Corporation Limited (HKG:6996)
2.840
-0.175 (-5.80%)
Oct 22, 2026, 4:08 PM HKT
Antengene Corporation Revenue
Antengene Corporation had revenue of 513.08M CNY in the half year ending June 30, 2026, with 744.17% growth. This brings the company's total for the last twelve months to 565.23M, up 570.08% year-over-year. In the year 2025, Antengene Corporation had annual revenue of 105.34M with 14.56% growth. That makes Antengene Corporation the 24,060th largest company in the world by revenue and 1,434th in Hong Kong.
Revenue (ttm)
565.23M CNY
Revenue Growth
+570.08%
P/S Ratio
3.18
Revenue / Employee
4.63M CNY
Employees
122
Market Cap
1.95B HKD
Revenue by Geography
- Mainland China 85.73M 81.4%
- Other Countries/Regions 19.61M 18.6%
Fiscal year ended Dec 31, 2025 See the full Antengene Corporation breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.34M | 13.39M | 14.56% |
| Dec 31, 2024 | 91.95M | 24.65M | 36.62% |
| Dec 31, 2023 | 67.31M | -92.83M | -57.97% |
| Dec 31, 2022 | 160.14M | 131.37M | 456.62% |
| Dec 31, 2021 | 28.77M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AIM Vaccine | 1.16B |
| Mabpharm | 888.77M |
| Shandong Boan Biotechnology | 720.87M |
| Medtide | 635.93M |
| BioDlink International Company | 582.45M |
| Laekna | 296.69M |
| Guangzhou Innogen Pharmaceutical Group | 176.96M |
| HJ Science | 16.30M |
Antengene Corporation News
- 4 weeks ago - Antengene Doses First Patient In Pivotal Phase III ATG-022 Gastric Cancer Trial; Stock Up - Nasdaq
- 2 months ago - Antengene Corporation Earnings release: H1 2026 - Filings
- 2 months ago - Antengene Corporation Slides: H1 2026 - Filings
- 2 months ago - Antengene Corporation Quarterly report: H1 2026 - Filings
- 4 months ago - Antengene Licenses ATG-106 And Grants Option Rights On Undisclosed Bispecific TCE To K2 Therapeutics - Nasdaq
- 7 months ago - Antengene Corporation Earnings release: H2 2025 - Filings
- 7 months ago - Antengene Corporation Slides: H2 2025 - Filings
- 7 months ago - Antengene Corporation Annual report: H2 2025 - Filings